InvestorsHub Logo
Followers 196
Posts 11520
Boards Moderated 0
Alias Born 11/29/2007

Re: davidsson10 post# 853

Friday, 08/26/2016 2:57:51 PM

Friday, August 26, 2016 2:57:51 PM

Post# of 1137
"Chalk up Nymox's rebound to persistent promotion and the willingness of traders to latch onto any stock with momentum. The company is certainly not surviving on fundamentals. Fexapotide is worth nothing. Including the most recent financing, Nymox has approximately 5 cents per share in cash. Yet at $4.34 per share, the company's market value exceeds $240 million."